Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) was downgraded by analysts at Needham & Company LLC to a “buy” rating in a note issued to investors on Thursday. They currently have a $137.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $152.00. Needham & Company LLC’s price objective suggests a potential upside of 299.77% from the stock’s current price.
Several other research firms have also weighed in on ALNY. Credit Suisse Group AG reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Cowen and Company reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Leerink Swann reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Zacks Investment Research raised Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 14th. Finally, JPMorgan Chase & Co. upped their price target on Alnylam Pharmaceuticals from $80.00 to $83.00 and gave the company an “overweight” rating in a research report on Friday, August 5th. Eight analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $80.88.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 34.27 on Thursday. The company’s 50-day moving average price is $70.69 and its 200 day moving average price is $66.05. The firm’s market capitalization is $2.94 billion. Alnylam Pharmaceuticals has a 52-week low of $33.16 and a 52-week high of $110.75.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The business earned $8.70 million during the quarter, compared to the consensus estimate of $8.09 million. During the same period in the prior year, the business posted ($0.85) earnings per share. Alnylam Pharmaceuticals’s revenue was up .2% compared to the same quarter last year. Equities research analysts predict that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current year.
In related news, CEO John Maraganore sold 30,151 shares of the stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the completion of the sale, the chief executive officer now owns 148,465 shares in the company, valued at approximately $9,604,200.85. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 4.00% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. Nisa Investment Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at $128,000. Seven Eight Capital LLC increased its stake in shares of Alnylam Pharmaceuticals by 200.0% in the first quarter. Seven Eight Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 1,800 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at $175,000. Bank of Montreal Can acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at $193,000. Finally, BlueMountain Capital Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 89.3% in the first quarter. BlueMountain Capital Management LLC now owns 3,179 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 1,500 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.